FDA
-
-
-
-
-
-
-
Silence Therapeutics (SLN) presents Phase 1 data on Divesiran
-
-
-
-
-
-
-
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
-
-
-
-
-
-
-
Silence Therapeutics (SLN) Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera
-
-
-
-
-
-
-
Silence Therapeutics Reports First Quarter 2022 Results
-
-
-
-
-
327,955 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

